Multiple meningiomas: Differential involvement of the NF2 gene in children and adults

Journal of Medical Genetics

Volumn 42, Issue 1, 2005, Pages 45-48

  Evans, D Gareth R ^a   Watson, C ^a   King, A ^b   Wallace, A J ^a   Baser, M E ^c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENOMIC DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; FAMILY HISTORY; GENE MUTATION; HUMAN; MALE; MENINGIOMA; MULTIPLE CANCER; NEURILEMOMA; NEUROFIBROMATOSIS; NF2 GENE; PRIORITY JOURNAL; SEIZURE; SYMPTOMATOLOGY; TUMOR SUPPRESSOR GENE; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; CHILD; GENES, NEUROFIBROMATOSIS 2; HUMANS; LOSS OF HETEROZYGOSITY; MENINGIOMA; MOSAICISM; MUTATION; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; POINT MUTATION; POLYMERASE CHAIN REACTION;

EID: 13244294112     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2004.023705     Document Type: Article

References (25)

1. Bondy M, Lignon BL. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol 1996;29:197-205.
2. Kuratsu J, Kochi M, Ushio Y. Incidence and clinical features of asymptomatic meningiomas. J Neurosurg 2000;92:766-70.
3. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
4. Harada T, Irving RM, Xuereb JH, Barton DE, Hardy DG, Moffat DA, Maher ER. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma. J Neurosurg 1996;84:847-51.
5. Lomszus K, Vahldiek F, Mautner VF, Schichor C, Tonn J, Stavron D, Filibrandt R, Westphal M, Kluwe L. Allelic losses in neurofibromatosis 2-associated meningiomas. J Neuropathol Exp Neurol 2000;59:504-12.
6. Leone PE, Bello MJ, de Campos JM, Vaquero J, Sarasa JL, Pestana A, Rey JA. NF2 mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 1999;18:2231-9.
7. Sulman EP, Dumanski JP, White PS, Khoo H, Maris JM, Mathiesen T, Bruder C, Cnaan A, Brodeur GM. Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. Cancer Res 1998;58:3226-30.
8. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000;9:1495-500.
9. Heinrich B, Hartmann C, Stemmer-Rachamimov AO, Louis DN, MacCollin M. Multiple meningiomas: investigating the molecular basis of sporadic and familial forms. Int J Cancer 2003;103:483-8.
10. Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, Weaver A, Gutmann DH. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000;59:872-9.
11. Evans DGR, Ramsden R, Birch J. Paediatric presentation of type 2 neurofibramatosis. Arch Dis Child 1999;81:496-9.
12. Perry A, Giannini C, Raghavan R, Scheithauer BW, Banerjee R, Margraf L, Bowers DC, Lytle RA, Newsham IF, Gutmann DH. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 2001;60:994-1003.
13. Wallace AJ, Wu C-L, Elles RG. Meta-PCR: a novel method for creating chimaeric DNA molecules and increasing the productivity of mutation screening techniques. Genetic Testing 1999;3:173-83.
14. Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannoma's. Neurology 2000;54:71-6.
15. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R. A genetic study of type 2 neurofibromatosis in the north west of England and the UK: I. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841-6.
16. Moyhuddin A, Baser ME, Watson C, Purcell S, Ramsden RT, Heiberg A, Wallace AJ, Evans DGR. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 2003;40:459-63.
17. Zhu JJ, Maruyama T, Jacoby LB, Herman JG, Gusella JF, Black PM, Wu JK. Clonal analysis of a case of multiple meningiomas using multiple molecular genetic approaches: pathology case report. Neurosurgery 1999;45:409-16.
18. Evans DGR, Wallace A, Trueman L, Wu C-L, Ramsden RT, Strachan T. Mosaicism in classical neurofibromatosis type 2: a common mechanism for sporadic disease in tumor prone syndromes? Am J Hum Genet 1998;63:727-36.
19. Maxwell M, Shih SD, Golanopoulos T, Hedley-Whyte ET, Cosgrove GR. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases. J Neurosurg 1998;88:562-9.
20. Lomas J, Bello MJ, Alonso ME, Gonzalez-Gomez P, Arjona D, Kusak ME, de Campos JM, Sarasa JL, Rey JA. Loss of chromosome 22 and absence of NF2 gene mutation in a case of multiple meningiomas. Hum Pathol 2002;33:375-8.
21. Pulst SM, Rouleau GA, Marineau C, Fain P, Sieb JP. Familial meningioma is not allelic to neurofibromatosis 2. Neurology 1993;43:2096-8.
22. Sadetzki S, Flint-Richter P, Ben-Tal T, Nass D. Radiation-induced meningioma: a descriptive study of 253 cases. J Neurosurg 2002;97:1078-82.
23. Evans JJ, Jeun SS, Lee JH, Harwalkar JA, Shoshan Y, Cowell JK, Golubic M. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas. J Neurosurg 2001;94:111-17.
24. Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Lekanne-Deprez R, Zwarthoff E. NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 2001;194:367-72.
25. Leone PE, Mendiola M, Alonso J, Paz-y-Mino C, Pestana A. Implications of a RAD54L polymorphism (2290C/T) in human meningiomas as a risk factor and/or a genetic marker. BMC Cancer 2003;3:6.